Hbk Investments LP Cut Its Bob Evans Farms (BOBE) Position; 5 Bullish Analysts Covering KemPharm (KMPH)

October 14, 2017 - By Peter Erickson

Hbk Investments LP decreased Bob Evans Farms Inc (BOBE) stake by 68.64% reported in 2017Q2 SEC filing. Hbk Investments LP sold 49,973 shares as Bob Evans Farms Inc (BOBE)’s stock rose 25.65%. The Hbk Investments LP holds 22,827 shares with $1.64 million value, down from 72,800 last quarter. Bob Evans Farms Inc now has $1.54B valuation. The stock decreased 0.09% or $0.07 on October 13, reaching $77.27. About 356,920 shares traded. Bob Evans Farms Inc (NASDAQ:BOBE) has risen 55.35% since October 14, 2016 and is uptrending. It has outperformed by 38.65% the S&P500.

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm has $55 highest and $7.0 lowest target. $19.40’s average target is 410.53% above currents $3.8 stock price. KemPharm had 14 analyst reports since August 14, 2015 according to SRatingsIntel. On Wednesday, June 28 the stock rating was maintained by Oppenheimer with “Buy”. The firm has “Buy” rating by Canaccord Genuity given on Thursday, September 17. The firm has “Outperform” rating by RBC Capital Markets given on Friday, August 14. Canaccord Genuity reinitiated the stock with “Buy” rating in Tuesday, December 20 report. The stock has “Buy” rating by Canaccord Genuity on Thursday, August 10. The rating was maintained by Oppenheimer on Friday, September 18 with “Outperform”. The stock of KemPharm Inc (NASDAQ:KMPH) has “Outperform” rating given on Friday, May 6 by RBC Capital Markets. The company was initiated on Wednesday, June 28 by Roth Capital. The stock has “Buy” rating by Oppenheimer on Thursday, August 10. The rating was maintained by Roth Capital with “Buy” on Friday, August 11. See KemPharm Inc (NASDAQ:KMPH) latest ratings:

11/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0 Maintain
11/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.0000 Maintain
10/08/2017 Broker: Oppenheimer Rating: Buy New Target: $13.0000 Maintain
10/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0000 Maintain
29/06/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0000
28/06/2017 Broker: Oppenheimer Rating: Buy New Target: $13.0000 Maintain
28/06/2017 Broker: Roth Capital Rating: Buy New Target: $8.0000 Initiate

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The company has market cap of $55.70 million. The Firm is engaged in the discovery and development of prodrugs. It currently has negative earnings. The Firm uses its Ligand Activated Therapy platform technology to create prodrugs.

The stock decreased 1.30% or $0.05 on October 13, reaching $3.8. About 35,237 shares traded. KemPharm Inc (NASDAQ:KMPH) has declined 32.16% since October 14, 2016 and is downtrending. It has underperformed by 48.86% the S&P500.

Investors sentiment increased to 1.42 in 2017 Q2. Its up 0.41, from 1.01 in 2017Q1. It improved, as 26 investors sold BOBE shares while 40 reduced holdings. 40 funds opened positions while 54 raised stakes. 15.16 million shares or 1.71% less from 15.43 million shares in 2017Q1 were reported. Comm National Bank has 0% invested in Bob Evans Farms Inc (NASDAQ:BOBE). Teachers Retirement Sys Of The State Of Kentucky holds 0.01% or 6,300 shares in its portfolio. Hbk Investments LP stated it has 0.02% in Bob Evans Farms Inc (NASDAQ:BOBE). Ls Inv Advisors Limited Liability Company holds 0% in Bob Evans Farms Inc (NASDAQ:BOBE) or 748 shares. Piedmont Investment Advsrs Limited Company invested 0.01% in Bob Evans Farms Inc (NASDAQ:BOBE). Old Mutual (Uk) Ltd holds 0.01% or 11,723 shares in its portfolio. Moreover, Parkside Financial Bank And Trust has 0% invested in Bob Evans Farms Inc (NASDAQ:BOBE) for 12 shares. Prudential Financial holds 0% or 37,064 shares in its portfolio. Aqr Management Limited Com stated it has 0% of its portfolio in Bob Evans Farms Inc (NASDAQ:BOBE). Credit Suisse Ag has invested 0% of its portfolio in Bob Evans Farms Inc (NASDAQ:BOBE). Ancora Advisors Limited has invested 0.41% of its portfolio in Bob Evans Farms Inc (NASDAQ:BOBE). Gsa Cap Partners Llp has 0.12% invested in Bob Evans Farms Inc (NASDAQ:BOBE) for 25,214 shares. Captrust Fincl Advisors owns 1,048 shares. Sector Pension Invest Board accumulated 10,253 shares. Balyasny Asset Management Lc invested in 266,450 shares or 0.08% of the stock.

Among 8 analysts covering Bob Evans Farms (NASDAQ:BOBE), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Bob Evans Farms had 17 analyst reports since August 31, 2015 according to SRatingsIntel. The rating was downgraded by Oppenheimer on Wednesday, January 4 to “Perform”. The rating was maintained by Maxim Group with “Buy” on Tuesday, June 13. The rating was maintained by Oppenheimer with “Hold” on Monday, June 26. William Blair downgraded the shares of BOBE in report on Friday, September 22 to “Hold” rating. Oppenheimer maintained the shares of BOBE in report on Wednesday, December 2 with “Outperform” rating. On Thursday, September 3 the stock rating was upgraded by Zacks to “Strong-Buy”. As per Thursday, December 3, the company rating was upgraded by Stephens. The rating was initiated by Maxim Group on Tuesday, May 17 with “Buy”. The rating was maintained by Oppenheimer with “Hold” on Wednesday, August 30. The rating was maintained by Maxim Group with “Buy” on Wednesday, December 7.

Analysts await Bob Evans Farms Inc (NASDAQ:BOBE) to report earnings on December, 4. They expect $0.35 earnings per share, down 37.50% or $0.21 from last year’s $0.56 per share. BOBE’s profit will be $6.98 million for 55.19 P/E if the $0.35 EPS becomes a reality. After $0.37 actual earnings per share reported by Bob Evans Farms Inc for the previous quarter, Wall Street now forecasts -5.41% negative EPS growth.